Exact Sciences (EXAS) Competitors $45.39 -0.21 (-0.46%) As of 03:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. ALNY, BIIB, UTHR, BMRN, INCY, NBIX, EXEL, RGEN, HALO, and MDGLShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Exact Sciences (NASDAQ:EXAS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability. Do insiders & institutionals have more ownership in EXAS or ALNY? 88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by company insiders. Comparatively, 1.2% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, EXAS or ALNY? Exact Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Does the MarketBeat Community prefer EXAS or ALNY? Alnylam Pharmaceuticals received 173 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.33% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.14% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformExact SciencesOutperform Votes99173.14% Underperform Votes36426.86% Alnylam PharmaceuticalsOutperform Votes116476.33% Underperform Votes36123.67% Does the media refer more to EXAS or ALNY? In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Exact Sciences. MarketBeat recorded 32 mentions for Alnylam Pharmaceuticals and 29 mentions for Exact Sciences. Alnylam Pharmaceuticals' average media sentiment score of 1.14 beat Exact Sciences' score of 0.90 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 14 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 24 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer EXAS or ALNY? Exact Sciences currently has a consensus target price of $69.25, indicating a potential upside of 52.33%. Alnylam Pharmaceuticals has a consensus target price of $315.58, indicating a potential upside of 25.46%. Given Exact Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Which has stronger earnings & valuation, EXAS or ALNY? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.76B3.06-$204.15M-$5.57-8.16Alnylam Pharmaceuticals$2.25B14.55-$278.16M-$2.17-115.92 Is EXAS or ALNY more profitable? Alnylam Pharmaceuticals has a net margin of -12.37% compared to Exact Sciences' net margin of -37.29%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-37.29% -5.29% -2.45% Alnylam Pharmaceuticals -12.37%N/A -6.83% SummaryAlnylam Pharmaceuticals beats Exact Sciences on 10 of the 19 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.46B$2.84B$5.39B$7.74BDividend YieldN/A31.34%5.44%4.32%P/E Ratio-8.1713.3122.0918.24Price / Sales3.06192.40397.71104.73Price / Cash8.7957.5638.2034.62Price / Book3.524.726.724.19Net Income-$204.15M-$22.21M$3.21B$247.59M7 Day Performance9.33%5.87%5.42%5.97%1 Month Performance-0.46%-2.51%-4.67%-3.59%1 Year Performance-22.67%16.21%17.72%4.84% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.2649 of 5 stars$45.39-0.5%$69.25+52.6%-27.9%$8.44B$2.76B-8.166,400Upcoming EarningsAnalyst RevisionNews CoverageALNYAlnylam Pharmaceuticals4.5991 of 5 stars$232.75-0.8%$315.58+35.6%+68.7%$30.28B$2.25B-107.262,000Upcoming EarningsAnalyst UpgradePositive NewsBIIBBiogen4.767 of 5 stars$116.49-1.8%$213.15+83.0%-40.8%$17.05B$9.68B10.418,720Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageUTHRUnited Therapeutics4.9206 of 5 stars$284.25-0.2%$395.67+39.2%+25.1%$12.77B$2.88B12.48980Upcoming EarningsAnalyst ForecastInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.8884 of 5 stars$58.65-0.9%$94.00+60.3%-31.2%$11.19B$2.85B26.663,080Upcoming EarningsINCYIncyte4.8682 of 5 stars$56.80-2.4%$74.69+31.5%+14.0%$10.99B$4.24B210.382,320Upcoming EarningsNBIXNeurocrine Biosciences4.8232 of 5 stars$100.68-0.7%$161.86+60.8%-23.9%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageEXELExelixis4.2988 of 5 stars$35.59-1.7%$37.59+5.6%+56.9%$9.96B$2.17B20.111,220Upcoming EarningsPositive NewsRGENRepligen4.5543 of 5 stars$131.64+1.3%$176.82+34.3%-13.5%$7.39B$634.44M-258.122,020Upcoming EarningsNews CoverageHALOHalozyme Therapeutics4.41 of 5 stars$57.29-2.6%$62.89+9.8%+51.5%$7.08B$1.02B16.70390Analyst ForecastNews CoverageMDGLMadrigal Pharmaceuticals4.4783 of 5 stars$295.02-2.2%$378.44+28.3%+56.3%$6.51B$180.13M-11.7690Analyst ForecastPositive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts